SINO BIOPHARM (01177): "Tulobuterol patch" approved for marketing.

SINO BIOPHARM (01177) announced that the group's developed "Tuloteroth patch" (trademark: Derituo) has been approved by the China National Medical Products Administration for marketing. The patch is used to relieve symptoms of respiratory difficulties caused by obstructive airway diseases such as asthma, acute bronchitis, chronic bronchitis, and emphysema. This is the first domestically produced patch for obstructive airway diseases to receive marketing approval. The Tuloteroth patch acts on the beta-2 receptors of bronchial smooth muscle, dilating the bronchi, relaxing bronchial muscles, improving lung function, promoting ciliary motility, and acting as an antitussive. Compared to traditional asthma treatment drugs, the Tuloteroth patch achieves systemic administration through transdermal delivery, avoiding first-pass metabolism in the liver, reducing gastrointestinal irritation, and maintaining stable blood drug levels, thus more effectively controlling asthma symptoms and providing a convenient and safe solution for long-term treatment of asthma, acute and chronic bronchitis, emphysema, and other obstructive airway diseases. The Tuloteroth patch is suitable for a wide range of people, including children aged six months and older. Compared to oral and inhaled formulations, the patch is simple and convenient to use, solving the problem of difficulty in administering medication to children and reducing medication errors due to improper handling. Derituo breaks the monopoly of imported medications and greatly alleviates the tense situation of childhood asthma medication in China. As a leading domestic transdermal formulation company, the group has over ten patches in the pipeline, covering pain relief, Parkinson's disease, insomnia, and other areas. Currently, the group has products such as Fluiban gel patch, Lidocaine gel patch, Loxofen sodium gel patch, and Lisodine transdermal patch approved for marketing. The group will accelerate the development and iteration of patch products, further enrich the product pipeline, and warm more lives with health technology.